These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7637141)

  • 21. Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department.
    Dowdy DW; Rodriguez RM; Hare CB; Kaplan B
    Acad Emerg Med; 2011 Jul; 18(7):745-53. PubMed ID: 21762236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee.
    Cain KP; Garman KN; Laserson KF; Ferrousier-Davis OP; Miranda AG; Wells CD; Haley CA
    Am J Respir Crit Care Med; 2012 Aug; 186(3):273-9. PubMed ID: 22561962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM; Christenson JC; Downs SM
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness.
    Snyder DC; Paz EA; Mohle-Boetani JC; Fallstad R; Black RL; Chin DP
    Am J Respir Crit Care Med; 1999 Jul; 160(1):178-85. PubMed ID: 10390397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a tuberculosis skin testing program.
    Kahn P
    J Sch Nurs; 2009 Feb; 25(1):48-54. PubMed ID: 19197018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for refractive error and fitting with spectacles in rural and urban India: cost-effectiveness.
    Frick KD; Riva-Clement L; Shankar MB
    Ophthalmic Epidemiol; 2009; 16(6):378-87. PubMed ID: 19995203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic analysis of a school-based obesity prevention program.
    Wang LY; Yang Q; Lowry R; Wechsler H
    Obes Res; 2003 Nov; 11(11):1313-24. PubMed ID: 14627751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
    Gourevitch MN; Alcabes P; Wasserman WC; Arno PS
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):531-40. PubMed ID: 9661818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries.
    Kowada A; Takasaki J; Kobayashi N
    J Hosp Infect; 2015 Feb; 89(2):99-108. PubMed ID: 25559158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of tobacco cessation support combined with tuberculosis screening among contacts who smoke.
    Kowada A
    Int J Tuberc Lung Dis; 2015 Jul; 19(7):857-63. PubMed ID: 26056114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuberculin skin test screening in schoolchildren in the United States.
    Driver CR; Valway SE; Cantwell MF; Onorato IM
    Pediatrics; 1996 Jul; 98(1):97-102. PubMed ID: 8668419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of screening for latent tuberculosis infection.
    Taylor Z
    Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S127-33. PubMed ID: 11144542
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany.
    Diel R; Nienhaus A; Loddenkemper R
    Chest; 2007 May; 131(5):1424-34. PubMed ID: 17494792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Universal screening for tuberculosis infection. School's out!
    Starke JR
    JAMA; 1995 Aug 23-30; 274(8):652-3. PubMed ID: 7637147
    [No Abstract]   [Full Text] [Related]  

  • 35. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis.
    Oxlade O; Schwartzman K; Menzies D
    Int J Tuberc Lung Dis; 2007 Jan; 11(1):16-26. PubMed ID: 17217125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.
    Pereira SM; Barreto ML; Pilger D; Cruz AA; Sant'Anna C; Hijjar MA; Ichihara MY; Santos AC; Genser B; Rodrigues LC
    Lancet Infect Dis; 2012 Apr; 12(4):300-6. PubMed ID: 22071248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevalence and costs of tuberculin screening performed at Altopiano di Asiago (Vicenza) during a decade].
    Demi M
    Pediatr Med Chir; 1997; 19(2):91-4. PubMed ID: 9312756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis.
    Mancuso JD; Niebuhr DW; Frick KD; Keep LW; Anderson KM
    Int J Tuberc Lung Dis; 2011 Sep; 15(9):1223-30, i. PubMed ID: 21943850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-optimisation of screening for latent tuberculosis in close contacts.
    Diel R; Nienhaus A; Lange C; Schaberg T
    Eur Respir J; 2006 Jul; 28(1):35-44. PubMed ID: 16571615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The economic evaluation of a health screening program on congenital heart disease for school children in Taichung, Taiwan.
    Chen FL; Pai JY
    Asia Pac J Public Health; 2008; 20(4):307-16. PubMed ID: 19124325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.